Esperion Therapeutics (ESPR) Payables (2018 - 2025)
Historic Payables for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $132.4 million.
- Esperion Therapeutics' Payables rose 27969.25% to $132.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $132.4 million, marking a year-over-year increase of 27969.25%. This contributed to the annual value of $106.2 million for FY2024, which is 23490.45% up from last year.
- Latest data reveals that Esperion Therapeutics reported Payables of $132.4 million as of Q3 2025, which was up 27969.25% from $129.5 million recorded in Q2 2025.
- Esperion Therapeutics' Payables' 5-year high stood at $132.4 million during Q3 2025, with a 5-year trough of $12.8 million in Q2 2022.
- Over the past 5 years, Esperion Therapeutics' median Payables value was $28.4 million (recorded in 2024), while the average stood at $46.6 million.
- In the last 5 years, Esperion Therapeutics' Payables tumbled by 6621.65% in 2021 and then skyrocketed by 34548.24% in 2025.
- Esperion Therapeutics' Payables (Quarter) stood at $17.6 million in 2021, then surged by 31.21% to $23.0 million in 2022, then skyrocketed by 37.66% to $31.7 million in 2023, then skyrocketed by 234.9% to $106.2 million in 2024, then increased by 24.62% to $132.4 million in 2025.
- Its Payables stands at $132.4 million for Q3 2025, versus $129.5 million for Q2 2025 and $126.7 million for Q1 2025.